Capricor Therapeutics’ (CAPR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report released on Thursday morning,Benzinga reports. They currently have a $77.00 price target on the biotechnology company’s stock.

CAPR has been the subject of a number of other research reports. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. Cantor Fitzgerald boosted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Finally, Maxim Group increased their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $14.96 on Thursday. The firm’s 50-day simple moving average is $16.82 and its 200 day simple moving average is $10.81. The firm has a market cap of $680.23 million, a price-to-earnings ratio of -14.11 and a beta of 3.98. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its position in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Capricor Therapeutics in the second quarter worth approximately $426,000. State Street Corp raised its holdings in Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after buying an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Capricor Therapeutics during the third quarter worth about $3,806,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Capricor Therapeutics during the third quarter valued at approximately $161,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.